The Center for Biosimilars® recaps the top 5 articles for the week of May 28, 2018.
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of May 28.
Number 5: Drug maker Lupin has announced that its marketing authorization application for a proposed etanercept biosimilar was accepted for review by the European Medicines Agency.
Number 4: A new study concludes that most patients can self-administer Boehringer Ingelheim’s adalimumab biosimilar, Cyltezo, using an auto-injector device.
Number 3: After having received a Complete Response Letter, biosimilar developer Celltrion has resubmitted its application for a proposed rituximab biosimilar, CT-P10, to the FDA.
Number 2: New research describes how much the European Union is overspending on neovascular age-related macular degeneration treatment by relying on ranibizumab and aflibercept rather than bevacizumab.
Number 1: FDA Commissioner Scott Gottlieb, MD, has announced new draft guidance documents aimed at limiting the potential for drug makers to abuse Risk Evaluation and Mitigation Strategy requirements.
Finally, last week, our e-newsletter asked whether you think that a recent study showing that 6 months of trastuzumab therapy is as good as 1 year will change clinical practice.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.